Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system eff... von Lu, S., Ahn, M.-J., Reungwetwattana, T., Özgüroğlu, M., Kato, T., Yang, J.C.-H., Huang, M., Fujiki, F., Inoue, T., Quang, L.-V., Sriuranpong, V., Vicente, D., Fuentes, C., Chaudhry, A.A., Poole, L., Armenteros Monterroso, E., Rukazenkov, Y., van der Gronde, T., Ramalingam, S.S.

Volltext

1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis von Dong, X., Jian, H., Huang, M., Yuan, S., Zhu, Z., Wu, L., Chen, M., Bi, N., Pan, Y., Wang, Y., Lv, D., Armenteros Monterroso, E., Huang, X., Liu, J., Fu, W., Zhao, Y., Lu, S.

Volltext

OA12.03 Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study von Kato, T., Dong, X., Takahashi, T., Soparattanapaisarn, N., Geater, S.L., Nguyen, K.V., Wang, C.-L., Arriola, E., Moiseenko, F., Thompson, L., Harker, S., Grainger, E., Armenteros-Monterroso, E., Bolanos, A., Ramalingam, S., Lu, S.

Volltext

630MO First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort von Yang, J.C-H., Kobayashi, K., Chewaskulyong, B., Tran, T.V., Biswas, B., Lee, K.H., Feng, P-H., Pham, X.D., Yao, Y., Kuyama, S., Chun Bing, J.Y. Tan, Bhise, R., Ahn, M-J., Sriuranpong, V., Li, R.K., Monterroso, E. Armenteros, Barrett, K., Albayaty, M., Cheng, Y.

Volltext

568P First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results von Planchard, D., Poltoratskiy, A., Kim, S-W., Kim, T.M., Yanagitani, N., Kagamu, H., Feng, P-H., Hughes, B., Yang, T-Y., Yang, J.C-H., Lee, C.K., Karaseva, N., Mitchell, P., Tambo, Y., Armenteros Monterroso, E., Todd, A., Sahasrabudhe, A., Jänne, P.A., Kobayashi, K.

Volltext

The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia von Armenteros-Monterroso, E, Zhao, L, Gasparoli, L, Brooks, T, Pearce, K, Mansour, MR, Martens, JHA, de Boer, J, Williams, O

Volltext bestellen

Systematic comparison of culture media and transduction enhancers for optimised CD34⁺ cell-based retroviral gene therapy protocols von Schott, JW, Leon-Rico, D, Armenteros-Monterroso, E, Buckland, KF, Rivat, C, Disakou, A, Pereira, I, Izotova, N, Booth, C, Thrasher, AJ

Volltext bestellen